Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181893 · ClinicalTrials.gov registry record · Phase 2
A Study In Adults With Moderate To Severe Dermatomyositis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT03181893 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 75 participants.
The verdict
NCT03181893, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
Interventions
- DRUG Placebo Arm
- DRUG PF-06823859 low
- DRUG PF-06823859 high
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-01-23 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181893
The ClinicalTrials.gov registry entry for NCT03181893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Arm is the first listed.
NCT03181893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03181893 about?
NCT03181893 is a clinical study titled "A Study In Adults With Moderate To Severe Dermatomyositis". A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
What is the current status of trial NCT03181893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2018-01-23. Estimated completion is 2022-11-28.
What interventions are being tested in trial NCT03181893?
The interventions under investigation include: Placebo Arm (DRUG), PF-06823859 low (DRUG), PF-06823859 high (DRUG).
Who is sponsoring clinical trial NCT03181893?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.